Clinical trials: Dementia, completed
Alzheimer's Disease, Vascular Dementia
Seroquel- Agitation Associated With Dementia
The purpose of this study is to determine how safe and effective Seroquel (quetiapine fumarate) is compared to placebo (a non-drug tablet) for a period of up to 10 weeks in the treatment of agitation symptoms in nursing home or…
- Trial name
- NCT00621647
- Testing
- Quetiapine Fumarate
- Volunteers
- 333 people
- Sponsor
- AstraZeneca
Psychiatric Disorder
Sensory Room at an Acute Psychiatric Unit
the aim of the presented study is to explore the effectiveness of a sensory room in reducing seclusion, restraint and aggression at an acute psychiatric ward.
- Trial name
- NCT05512858
- Testing
- sensory room
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Tel Aviv University
Schizophrenia
A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation
This local registration study is to confirm the hypothesis of the efficacy, tolerability and safety of ziprasidone IM (intramuscular) in the Chinese population with agitation in schizophrenia
- Trial name
- NCT00723606
- Testing
- Intramuscular ziprasidone mesylate, Intramuscular haloperidol
- Where
- 9 sites in China
- Volunteers
- 376 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Alzheimer's Disease Neuroimaging Initiative 3
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD.
- Trial name
- ADNI3 (NCT02854033)
- Where
- 59 sites in United States, Canada
- Volunteers
- 1,141 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Alzheimer Disease, Healthy Volunteers
A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease
This study is being done for the following reasons: To determine the safety of LY2886721 and any side effects that may be associated with it and to see how much of the study drug is in the blood and the cerebrospinal fluid (CSF)…
- Trial name
- NCT01807026
- Testing
- LY2886721
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Sarcopenia, Sarcopenic Obesity
Effects of a Multi-intervention Programme for the Elderly
1. To develop a multiactivity training programme. 2. To explore the effect of this programme on sarcopenia, sarcopenic obesity, cognitive impairment and Parkinson's disease. 3.
- Conditions
- Sarcopenia, Sarcopenic Obesity, Dementia
- Trial name
- NCT05720416
- Testing
- protein supplementation, muscle strength training, usual care
- Where
- Taiwan
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Central Taiwan University of Science and Technology
Dementia, Prisoners
Computer-Based Learning to Enhance Dementia Care in Prison
The mission of corrections is to provide care, custody, and control for incarcerated individuals. United States prisons are required by law to provide adequate care for growing numbers of older people who are incarcerated-a group…
- Trial name
- NCT05497882
- Testing
- E-Learning Prototype for Dementia Care
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Klein Buendel, Inc.
Alzheimer's Disease, Huntington Disease
A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)
This study will evaluate four different modified release formulation to estimate the amount of dimebon available to the body relative to the current dimebon formulation that is given three times a day.
- Trial name
- NCT00988624
- Testing
- Dimebon IR Tablet, Dimebon MR1, Dimebon MR2
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer's Disease
A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects
This is a randomized, double-blind (Investigator and subject-blinded) placebo-controlled, multiple, ascending-dose study to evaluate the safety, tolerability, and pharmacokinetic profile of BPN14770 in healthy young and elderly…
- Trial name
- NCT02840279
- Testing
- BPN14770
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Tetra Discovery Partners
Mild Cognitive Impairment, Alzheimer Disease
Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease
This study will perform a targeted metabolic analysis in blood and urine samples from subjects attending the Baylor AT\&T Memory Center.
- Trial name
- BVB (NCT03136679)
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Baylor Research Institute
Alzheimer's Disease, Cardiovascular Risk Factors
Impact of Controlling Vascular Risk Factors on the Progression of Alzheimer's Disease
Three quarters of patients with Alzheimer's disease have at least one vascular risk factor (VRF). Vascular brain lesions are present in most Alzheimer's patients (especially older ones).
- Trial name
- COVARAD (NCT01423396)
- Testing
- optimal care of VRF, standard care
- Where
- 21 sites in France
- Volunteers
- 304 people
- Sponsor
- University Hospital, Lille
Parkinson Disease, Dementia
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
This study evaluates the benefits of exoskeleton-based exercise for improving mood and cognition in people with Parkinson's disease (PD).
- Conditions
- Parkinson Disease, Dementia, Mild Cognitive Impairment
- Trial name
- NCT03583879
- Testing
- Exoskeleton exercise, Standard exercise, No treatment
- Where
- 2 sites in Canada
- Volunteers
- 41 people
- Sponsor
- University of New Brunswick
HIV-Associated Cognitive Motor Complex, Aging
Individualized Cognitive Training in HIV
Over 50% of adults with HIV have some form of HIV-Associated Neurocognitive Disorder (HAND) which represents a significant symptom that interferes with everyday functioning and quality of life.
- Conditions
- HIV-Associated Cognitive Motor Complex, Aging, Cognitive Impairment, Cognitive Decline
- Trial name
- TOPS (NCT03122288)
- Testing
- Individualized Cognitive Training, No-Contact Control
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- University of Alabama at Birmingham
Validate the French Version of GMS Package
Validation of the French Version of the Geriatric Mental State (GMS)
A major public health issues of today's aging population is the development of knowledge and expertise in geriatric medicine and psychiatry of the elderly.
- Trial name
- GMS-Package (NCT01061827)
- Where
- 2 sites in France
- Volunteers
- 96 people
- Sponsor
- University Hospital, Tours
Schizophrenia
Clozapine and Olanzapine Treatment of Aggression
This was a double-blind randomized study with three treatment arms: clozapine, olanzapine and haloperidol. We compared these three medications in the treatment of aggressive behavior over a 12 week period.
- Trial name
- NCT01123408
- Testing
- Clozapine, Olanzapine, Haloperidol
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Dementia Prevention
e-Learning About Cognitive Impairment and Dementia Prevention
In this proposal, the investigators plan to study the effectiveness of our web-based intervention on dementia prevention knowledge, intentions, and behaviour change.
- Trial name
- NCT05383118
- Testing
- Education Intervention, Education Control
- Where
- Canada
- Volunteers
- 536 people, healthy volunteers welcome
- Sponsor
- McMaster University
Parkinson Disease, Alzheimer Disease
Effectiveness of Probiotic K10 in Managing Health Outcomes in Parkinson and Alzheimer Disease
Evaluation of the effects of the K10 probiotic mix in patients with degenerative neurological diseases (Parkinson and Alzheimer's) with a focus on cognitive, motor and psychiatric neurological evaluation.
- Trial name
- Probiótico (NCT06019117)
- Testing
- Probiotic K10
- Where
- Brazil
- Volunteers
- 104 people
- Sponsor
- Deivis de Oliveira guimaraes
Alzheimer's Disease
A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)
This study is designed to confirm the efficacy, the tolerability, the patient compliance and the caregiver satisfaction with rivastigmine target patch size 10 cm^2 in patients with probable Alzheimer's Disease (Mini-Mental State…
- Trial name
- EXTRA (NCT00622713)
- Testing
- Rivastigmine transdermal patch
- Where
- France
- Volunteers
- 228 people
- Sponsor
- Novartis
Alzheimer's Disease, Amyotrophic Lateral Sclerosis
Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.
This is a prospective investigation of the effects of Laughter therapy (LT) on perceived stress, self-efficacy, mood and other wellness measures in people with the following neurological conditions: Alzheimer's disease…
- Conditions
- Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Brain Injury, Huntington's Disease
- Trial name
- NCT02750982
- Testing
- Laughter Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Brown, Theodore R., M.D., MPH
Alzheimer's Disease
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of E2609 when administered as single doses to healthy adult volunteers and healthy elderly subjects.
- Trial name
- NCT01294540
- Testing
- Drug: E2609
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.